Lamotrigine for neuroprotection in secondary progressive multiple sclerosis: a randomised, double-blind, placebo-controlled, parallel-group trial

The Lancet Neurology

Volumn 9, Issue 7, 2010, Pages 681-688

  Kapoor, Raju ^a   Furby, Julian ^a   Hayton, Thomas ^a   Smith, Kenneth J ^a   Altmann, Daniel R ^a,b   Brenner, Robert ^c   Chataway, Jeremy ^a   Hughes, Richard AC ^a   Miller, David H ^a  

^a NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^c ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

LAMOTRIGINE; PLACEBO;

ADULT; ANEMIA; ARTICLE; BRAIN SIZE; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFECT; FEMALE; GAIT DISORDER; HUMAN; LIMB FRACTURE; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NAUSEA; NEUROPROTECTION; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; PHYSICIAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; RELAPSE; STROKE; SUBDURAL HEMATOMA;

ADOLESCENT; ADULT; BRAIN INFARCTION; DISABILITY EVALUATION; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; MOVEMENT DISORDERS; MULTIPLE SCLEROSIS; NEUROPROTECTIVE AGENTS; SEVERITY OF ILLNESS INDEX; TRIAZINES; WALKING; YOUNG ADULT;

EID: 77953476309     PISSN: 14744422     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1474-4422(10)70131-9     Document Type: Article

References (33)

1. Compston A., and Coles A.J. Multiple sclerosis. Lancet 359 (2002) 1221-1231
2. Goodin D.S., Frohman E.M., Garmany Jr. G.P., et al. Disease modifying therapies in multiple sclerosis: report of the therapeutics and technology assessment subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology 58 (2002) 169-178
3. Frohman E.M., Filippi M., Stuve O., et al. Characterizing the mechanisms of progression in multiple sclerosis: evidence and new hypotheses for future directions. Arch Neurol 62 (2005) 1345-1356
4. Stys P.K. General mechanism of axonal damage and its prevention. J Neurol Sci 233 (2005) 3-13
5. Garthwaite G., Goodwin D.A., Batchelor A.M., et al. Nitric oxide toxicity in CNS white matter: an in vitro study using rat optic nerve. Neuroscience 109 (2002) 145-155
6. Lo A.C., Saab C.Y., Black J.A., and Waxman S.G. Phenytoin protects spinal cord axons and preserves axonal conduction and neurological function in a model of neuroinflammation in vivo. J Neurophysiol 90 (2003) 3566-3571
7. Kapoor R., Davies M., Blaker P.A., et al. Blockers of sodium and calcium entry protect axons from nitric oxide-mediated degeneration. Ann Neurol 53 (2003) 174-180
8. Bechtold D.A., Kapoor R., and Smith K.J. Axonal protection using flecainide in experimental autoimmune encephalomyelitis. Ann Neurol 55 (2004) 607-616
9. Bechtold D.A., Miller S.J., Dawson A.C., et al. Axonal protection achieved in a model of multiple sclerosis using lamotrigine. J Neurol 253 (2006) 1542-1551
10. Losseff N., Wang L., Lai H.M., et al. Progressive cerebral atrophy in multiple sclerosis: a serial MRI study. Brain 119 (1996) 2009-2019
11. Black J.A., Liu S., Carrithers M., et al. Exacerbation of experimental autoimmune encephalomyelitis after withdrawal of phenytoin and carbamazepine. Ann Neurol 62 (2007) 21-33
12. Freeborough P.A., Fox N.C., and Kitney R.I. Interactive algorithms for the segmentation and quantitation of 3-D MRI brain scans. Comput Methods Programs Biomed 53 (1997) 15-25
13. Studholme C., Hill D.L.G., and Hawkes D.J. An overlap invariant entropy measure of 3D medical image alignment. Pattern Recognit 32 (1999) 71-86
14. Asburner J., and Friston K. Multimodal image coregistration and partitioning-a unified framework. Neuroimage 6 (1997) 209-217
15. Losseff N., Webb S.L., Riordan J.I., et al. Spinal cord atrophy and disability in multiple sclerosis: a new reproducible and sensitive MRI method with potential to monitor disease progression. Brain 119 (1996) 701-708
16. Altmann D.R., Jasperse B., Barkhof F., et al. Sample sizes for brain atrophy outcomes in trials for secondary progressive multiple sclerosis. Neurology 72 (2009) 595-601
17. Verbeke G., and Molenberghs G. Linear mixed models for longitudinal data (2000), Springer-Verlag, New York, USA
18. Hoogervorst E.L., Kalkers N.F., Uitdehaag B.M., and Polman C.H. A study validating changes in the multiple sclerosis functional composite. Arch Neurol 59 (2002) 113-116
19. Armitage P., Berry G., and Matthews J. Statistical Methods in Medical Research. 4th edn. (2002), Blackwell Science, Oxford, UK
20. Kutzelnigg A., Lucchinetti C.F., Stadelmann C., et al. Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain 128 (2005) 2705-2712
21. Fisher E., Lee J.-C., Nakamura K., and Rudick R.A. Grey matter atrophy in multiple sclerosis: a longitudinal study. Ann Neurol 64 (2008) 255-265
22. Rudick R.A., Fisher E., Lee J.-C., et al. Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS. Neurology 53 (1999) 1698-1704
23. Frank J.A., Richert N., Bash C., et al. Interferon-beta-1b slows progression of atrophy in RRMS: three-year follow-up in NAb- and Nab+ patients. Neurology 62 (2004) 719-725
24. Hardmeier M., Wagenpfeil S., Freitag P., et al. Rate of brain atrophy in relapsing MS decreases during treatment with IFNbeta-1a. Neurology 64 (2005) 236-240
25. Miller D.H., Soon D., Fernando K.T., et al. MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS. Neurology 68 (2007) 1390-1401
26. Zivadinov R., Reder A.T., Filippi M., et al. Mechanisms of action of disease-modifying agents and brain volume changes in multiple sclerosis. Neurology 71 (2008) 136-144
27. Black J.A., Newcombe J., Trapp B.D., and Waxman S.G. Sodium channel expression within chronic multiple sclerosis plaques. J Neuropath Exp Neurol 66 (2007) 828-837
28. Leandri M., Lunardi G., Inglese M., et al. Lamotrigine in trigeminal neuralgia secondary to multiple sclerosis. J Neurol 247 (2000) 556-558
29. Bosma L., Kragt J.J., Brieva L., et al. The search for responsive clinical endpoints in primary progressive multiple sclerosis. Mult Scler 15 (2009) 715-720
30. Craner M.J., Damarjian T.G., Liu S., et al. Sodium channels contribute to microglia/macrophage activation and function in EAE and MS. Glia 15 (2005) 220-229
31. Dalton C.M., Chard D.T., Davies G.R., et al. Early development of multiple sclerosis is associated with progressive grey matter atrophy in patients presenting with clinically isolated syndromes. Brain 127 (2004) 1101-1107
32. Sanfilipo M.P., Benedict R.H.B., Sharma J., et al. The relationship between whole brain volume and disability in multiple sclerosis: a comparison of normalized gray vs. white matter with misclassification correction. Neuroimage 26 (2005) 1068-1077
33. Barkhof F., Calabresi P.A., Miller D.H., and Reingold S.C. Imaging outcomes for neuroprotection and repair in multiple sclerosis trials. Nat Rev Neurol 5 (2009) 256-266